AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Medicover

Declaration of Voting Results & Voting Rights Announcements Nov 30, 2022

2943_rns_2022-11-30_09e2af79-d508-4232-bb4c-5c73c045d1f9.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Press Release Stockholm, 30 November 2022

NUMBER OF SHARES AND VOTES IN MEDICOVER

The number of votes in Medicover AB (publ) ("Medicover") has changed as a result of conversions of in total 24,400 class A shares into B shares carried out in November following requests from shareholders in accordance with the conversion clause in Medicover's articles of association.

Today, the last trading day of the month, there are in total 151,935,195 shares in Medicover, of which 77,374,876 are class A shares, together carrying 77,374,876 votes, 71,578,691 are class B shares, together carrying 7,157,869.1 votes and 2,981,628 are class C shares, together carrying 298,162.8 votes. The total number of votes in Medicover is 84,830,907.9.

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations

+46 703 033 272 [email protected]

Medicover is required to publish the information contained in this press release pursuant to the Swedish Financial Instruments Trading Act. The information was provided for publication by the abovementioned contact person at 10.00 CET on 30 November 2022.

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2021, Medicover had revenue of EUR 1,377 million and more than 38,000 employees. For more information, go to www.medicover.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.